Geographic Atrophy (GA): Symptoms, Treatment & Specialist AMD Care in Reading & Windsor
What is Geographic atrophy (GA)?
Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD) that causes gradual, permanent damage to the macula—the specialised part of the retina responsible for detailed central vision. Although geographic atrophy does not usually cause complete blindness, it can significantly affect reading, recognising faces, watching television, driving and other everyday activities.
The term “geographic” refers to the map-like areas of retinal cell loss that can develop and gradually enlarge over time. Geographic atrophy can affect one or both eyes, and its progression varies considerably between individuals.
What are the symptoms of geographic atrophy?
Early geographic atrophy may cause surprisingly few symptoms. As areas of retinal damage enlarge, patients may notice:
-
Blurred or missing areas in central vision
-
Difficulty reading small print
-
Difficulty recognising faces
-
Reduced contrast, particularly in dim lighting
-
Needing brighter light to read or perform close-up tasks
-
Difficulty seeing fine detail
-
A gradual reduction in confidence with everyday activities
Peripheral vision is generally preserved, which means that people with geographic atrophy are not necessarily going blind. However, the loss of central vision can have a major impact on independence and quality of life.
Any sudden change in vision, new distortion or a new central dark or blurred area should be assessed promptly because people with dry AMD can also develop wet AMD (neovascular AMD), which requires urgent treatment.
.jpeg)
How is geographic atrophy diagnosed?
A specialist retinal assessment is important when geographic atrophy is suspected. Diagnosis usually involves a detailed examination of the retina together with imaging such as optical coherence tomography (OCT), fundus autofluorescence, colour fundus photography and, where appropriate, other specialised retinal imaging.
These investigations help the ophthalmologist determine the location and extent of geographic atrophy, assess whether it is progressing and look for signs of wet AMD or other retinal conditions.
Regular monitoring remains important even when the condition appears stable.
This is because the possibility of turning to wet macular degeneration remains.
What is the management of geographic atrophy?
Management of GA is individualised. At present, there is no treatment that can replace retinal cells that have already been lost. However, there are several important ways of managing geographic atrophy and protecting visual function.
1. Regular retinal monitoring
Regular review allows changes in the macula to be detected and helps identify the development of wet AMD at an early stage. Possibility of expansion of atrophic areas can be checked by regular OCT scans and FAF scans.Home monitoring of vision may also be recommended, particularly if there is a significant risk of progression.
2. Lifestyle and AMD risk-factor management
Patients should be encouraged to stop smoking if they smoke, maintain a healthy diet and cardiovascular health, exercise appropriately and attend regular eye examinations. An ophthalmologist can advise whether an AREDS2-type nutritional supplement is appropriate, as supplements are not suitable for everyone and do not reverse established geographic atrophy.
3. Emerging and specialist treatments
Research into geographic atrophy treatment is progressing rapidly, particularly treatments targeting the complement system, an important part of the body's immune response. Complement-inhibitor therapies have demonstrated an ability to slow the growth of atrophic lesions in clinical trials, although availability and licensing vary between countries and treatment suitability depends on individual circumstances. Some previously proposed medicines have not proceeded to European approval, highlighting why treatment decisions should be based on current evidence and specialist advice.
4. Photobiomodulation (PBM)
Photobiomodulation (PBM) is an emerging treatment being investigated for dry AMD and geographic atrophy. It uses specific wavelengths of light with the aim of influencing cellular and mitochondrial function in the retina.
PBM is an area of considerable research interest, but patients should understand that it is not yet an established cure for geographic atrophy. Current evidence remains limited, and it an area generating interest and studies are trying to demonstrate a clinically meaningful benefit for GA, with concerns about study size and quality.
For this reason, PBM should be discussed with a retinal specialist in the context of the individual's diagnosis, available evidence and treatment options.
Low vision aids and rehabilitation
When geographic atrophy affects central vision, low vision rehabilitation can make a remarkable practical difference. A low vision assessment can identify the best combination of optical and electronic aids for a patient's particular needs.
Options may include magnifying glasses, illuminated magnifiers, high-powered reading aids, electronic magnification, telescopic devices, larger print, improved lighting and smartphone or computer accessibility features. Training in visual strategies, including eccentric viewing, can help some people use healthier areas of the retina to make better use of their remaining vision.
The aim is not simply to measure how much vision has been lost, but to help patients continue doing the things that matter to them.
The role of an ECLO
An Eye Clinic Liaison Officer (ECLO) can provide invaluable practical and emotional support following a diagnosis of AMD or geographic atrophy. ECLOs can explain available services, provide information about living with sight loss, support families and carers, and signpost patients towards financial, employment, rehabilitation and emotional support.
Patients should ask their eye clinic whether an ECLO or sight-loss adviser is available.
Support from sight-loss organisations
Patients and families do not have to manage geographic atrophy alone. Organisations such as the Macular Society provide information, local support groups, helpline services, counselling and practical advice for people living with macular disease.
The RNIB and Berkshire Vision provides extensive information about AMD, low vision, assistive technology, ECLO services and living independently with sight loss. Visionary connects people with local sight-loss organisations across the UK, while organisations such as Thomas Pocklington Trust, Retina UK, Guide Dogs and Blind Veterans UK can provide additional support depending on individual circumstances.
What is the management of geographic atrophy?
Management of GA is individualised. At present, there is no treatment that can replace retinal cells that have already been lost. However, there are several important ways of managing geographic atrophy and protecting visual function.
1. Regular retinal monitoring
Regular review allows changes in the macula to be detected and helps identify the development of wet AMD at an early stage. Home monitoring of vision may also be recommended, particularly if there is a significant risk of progression.
2. Lifestyle and AMD risk-factor management
Patients should be encouraged to stop smoking if they smoke, maintain a healthy diet and cardiovascular health, exercise appropriately and attend regular eye examinations. An ophthalmologist can advise whether an AREDS2-type nutritional supplement is appropriate, as supplements are not suitable for everyone and do not reverse established geographic atrophy.
3. Emerging and specialist treatments
Research into geographic atrophy treatment is progressing rapidly, particularly treatments targeting the complement system, an important part of the body's immune response. Complement-inhibitor therapies have demonstrated an ability to slow the growth of atrophic lesions in clinical trials, although availability and licensing vary between countries and treatment suitability depends on individual circumstances. Some previously proposed medicines have not proceeded to European approval, highlighting why treatment decisions should be based on current evidence and specialist advice.
4. Photobiomodulation (PBM)
Photobiomodulation (PBM) is an emerging treatment being investigated for dry AMD and geographic atrophy. It uses specific wavelengths of light with the aim of influencing cellular and mitochondrial function in the retina.
PBM is an area of considerable research interest, but patients should understand that it is not yet an established cure for geographic atrophy. Current evidence remains limited, and a systematic review and meta-analysis found insufficient evidence to demonstrate a clinically meaningful benefit for GA, with concerns about study size and quality. PPubMed
For this reason, PBM should be discussed with a retinal specialist in the context of the individual's diagnosis, available evidence and treatment options.
Low vision aids and rehabilitation
When geographic atrophy affects central vision, low vision rehabilitation can make a remarkable practical difference. A low vision assessment can identify the best combination of optical and electronic aids for a patient's particular needs.
Options may include magnifying glasses, illuminated magnifiers, high-powered reading aids, electronic magnification, telescopic devices, larger print, improved lighting and smartphone or computer accessibility features. Training in visual strategies, including eccentric viewing, can help some people use healthier areas of the retina to make better use of their remaining vision.
The aim is not simply to measure how much vision has been lost, but to help patients continue doing the things that matter to them.
Specialist geographic atrophy and AMD care in Reading and Windsor
For patients seeking specialist advice about geographic atrophy, dry AMD or wet AMD in Reading and Windsor, Mr Praveen Kumar offers extensive experience in medical retina and AMD care. He is a Consultant Ophthalmologist with more than 35 years of ophthalmology experience, including 18 years specialising in AMD, and is currently Lead Consultant for AMD at the Prince Charles Eye Unit in Windsor, as well as a senior medical retinal specialist in Reading. His experience includes the assessment and management of complex AMD and involvement in research into emerging treatments for geographic atrophy. For anyone diagnosed with geographic atrophy, the most important message is that loss of central vision does not mean loss of independence. Early specialist assessment, appropriate monitoring, management of AMD risk factors, access to emerging treatments where appropriate, and timely low-vision rehabilitation can all play an important role in maintaining quality of life.
Summary of types of clinically significant AMD
-
Intermediate AMD:Generally corresponds to early AMD with medium/high risk of progression, such as large drusen, reticular pseudodrusen and associated pigmentary abnormalities.
-
Late AMD (indeterminate): Late-stage AMD changes with subretinal/intraretinal fluid but no detectable neovascularisation, or serous PED without neovascularisation.
-
Late AMD (wet active):Neovascular AMD with demonstrable neovascularisation and activity. (WET AMD)
-
Late AMD (dry):Geographic atrophy without neovascular AMD.
-
The RCOphth/NICE classification therefore makes clear that “intermediate AMD” and “late AMD (indeterminate)” describe very different clinical situations.